GRAL · GRAIL reported Q3 2026 total revenue of $37.5M (+4% YoY), below the…

GRAIL reported Q3 2026 total revenue of $37.5M (+4% YoY), below the $44.2M consensus, and GAAP EPS of -$2.21, worse than the consensus estimate of -$1.90. Galleri test volume grew 24% YoY to over 56,000 tests, but revenue growth decelerated to 14% YoY for Galleri. The FDA Advisory Committee voted favorably for Galleri approval in September, with an FDA decision expected by early Q1 2027. Net loss widened to $103.6M from $89.0M a year ago, and cash burn continues with cash and securities at $788.7M.

• Total revenue $37.5M, +4% YoY, below $44.2M consensus
• Galleri revenue $37.3M, +14% YoY (decelerated from +37% in Q1 2026)
• GAAP EPS -$2.21, worse than consensus -$1.90
• Net loss $103.6M, widened 16% from $89.0M a year ago